These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38319842)

  • 1. Rivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis.
    Plessier A; Goria O; Cervoni JP; Ollivier I; Bureau C; Poujol-Robert A; Minello A; Houssel-Debry P; Rautou PE; Payancé A; Scoazec G; Bruno O; Corbic M; Durand F; Vilgrain V; Paradis V; Boudaoud L; de Raucourt E; Roy C; Gault N; Valla D
    NEJM Evid; 2022 Dec; 1(12):EVIDoa2200104. PubMed ID: 38319842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.
    Khorana AA; Soff GA; Kakkar AK; Vadhan-Raj S; Riess H; Wun T; Streiff MB; Garcia DA; Liebman HA; Belani CP; O'Reilly EM; Patel JN; Yimer HA; Wildgoose P; Burton P; Vijapurkar U; Kaul S; Eikelboom J; McBane R; Bauer KA; Kuderer NM; Lyman GH;
    N Engl J Med; 2019 Feb; 380(8):720-728. PubMed ID: 30786186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis.
    Hanafy AS; Abd-Elsalam S; Dawoud MM
    Vascul Pharmacol; 2019 Feb; 113():86-91. PubMed ID: 29886103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy and safety between rivaroxaban and dabigatran in the treatment of acute portal vein thrombosis in cirrhosis.
    Zhou H; Wu M; Yu S; Xia H; Yu W; Huang K; Chen Y
    BMC Gastroenterol; 2023 Sep; 23(1):329. PubMed ID: 37749527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis.
    Field TS; Dizonno V; Almekhlafi MA; Bala F; Alhabli I; Wong H; Norena M; Villaluna MK; King-Azote P; Ratnaweera N; Mancini S; Van Gaal SC; Wilson LK; Graham BR; Sposato LA; Blacquiere D; Dewar BM; Boulos MI; Buck BH; Odier C; Perera KS; Pikula A; Tkach A; Medvedev G; Canfield C; Mortenson WB; Nadeau JO; Alshimemeri S; Benavente OR; Demchuk AM; Dowlatshahi D; Lanthier S; Lee AYY; Mandzia J; Suryanarayan D; Weitz JI; Hill MD;
    Stroke; 2023 Nov; 54(11):2724-2736. PubMed ID: 37675613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.
    Samama CM; Laporte S; Rosencher N; Girard P; Llau J; Mouret P; Fisher W; Martínez-Martín J; Duverger D; Deygas B; Presles E; Cucherat M; Mismetti P;
    N Engl J Med; 2020 May; 382(20):1916-1925. PubMed ID: 32223113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban plus aspirin versus acenocoumarol to manage recurrent venous thromboembolic events despite systemic anticoagulation with rivaroxaban.
    Maximiliano CL; Jaime GC; Erika MH
    Thromb Res; 2023 Feb; 222():43-48. PubMed ID: 36565679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial.
    Piazza G; Spyropoulos AC; Hsia J; Goldin M; Towner WJ; Go AS; Bull TM; Weng S; Lipardi C; Barnathan ES; Bonaca MP;
    Circulation; 2023 Jun; 147(25):1891-1901. PubMed ID: 37154020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.
    Beyer-Westendorf J; Schellong SM; Gerlach H; Rabe E; Weitz JI; Jersemann K; Sahin K; Bauersachs R;
    Lancet Haematol; 2017 Mar; 4(3):e105-e113. PubMed ID: 28219692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial.
    Ageno W; Bertù L; Bucherini E; Camporese G; Dentali F; Iotti M; Lessiani G; Parisi R; Prandoni P; Sartori M; Visonà A; Bigagli E; Palareti G;
    BMJ; 2022 Nov; 379():e072623. PubMed ID: 36520715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the incidence of bleeding in patients prescribed rivaroxaban for the treatment and prevention of deep vein thrombosis and pulmonary embolism in UK secondary care: an observational cohort study.
    Evans A; Davies M; Osborne V; Roy D; Shakir S
    BMJ Open; 2020 Nov; 10(11):e038102. PubMed ID: 33148732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.
    Male C; Lensing AWA; Palumbo JS; Kumar R; Nurmeev I; Hege K; Bonnet D; Connor P; Hooimeijer HL; Torres M; Chan AKC; Kenet G; Holzhauer S; Santamaría A; Amedro P; Chalmers E; Simioni P; Bhat RV; Yee DL; Lvova O; Beyer-Westendorf J; Biss TT; Martinelli I; Saracco P; Peters M; Kállay K; Gauger CA; Massicotte MP; Young G; Pap AF; Majumder M; Smith WT; Heubach JF; Berkowitz SD; Thelen K; Kubitza D; Crowther M; Prins MH; Monagle P;
    Lancet Haematol; 2020 Jan; 7(1):e18-e27. PubMed ID: 31699660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Band ligation versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children and adolescents with chronic liver disease or portal vein thrombosis.
    Cifuentes LI; Gattini D; Torres-Robles R; Gana JC
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD011561. PubMed ID: 33522602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.
    Anderson DR; Dunbar M; Murnaghan J; Kahn SR; Gross P; Forsythe M; Pelet S; Fisher W; Belzile E; Dolan S; Crowther M; Bohm E; MacDonald SJ; Gofton W; Kim P; Zukor D; Pleasance S; Andreou P; Doucette S; Theriault C; Abianui A; Carrier M; Kovacs MJ; Rodger MA; Coyle D; Wells PS; Vendittoli PA
    N Engl J Med; 2018 Feb; 378(8):699-707. PubMed ID: 29466159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Prospective Observational Study.
    Lv Y; Bai W; Li K; Wang Z; Guo W; Luo B; Wang J; Wang Q; Wang E; Xia D; Li X; Yuan J; Han N; Niu J; Yin Z; Fan D; Han G
    Am J Gastroenterol; 2021 Jul; 116(7):1447-1464. PubMed ID: 33630766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral rivaroxaban for symptomatic venous thromboembolism.
    ; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
    N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
    Greenberg B; Neaton JD; Anker SD; Byra WM; Cleland JGF; Deng H; Fu M; La Police DA; Lam CSP; Mehra MR; Nessel CC; Spiro TE; van Veldhuisen DJ; Vanden Boom CM; Zannad F
    JAMA Cardiol; 2019 Jun; 4(6):515-523. PubMed ID: 31017637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of long-term anticoagulant treatment for the secondary prophylaxis of splanchnic venous thrombosis.
    Serrao A; Merli M; Lucani B; Aprile F; Fiori L; Gioia S; Breccia M; Riggio O; Chistolini A
    Eur J Clin Invest; 2021 Jan; 51(1):e13356. PubMed ID: 33180323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis.
    La Mura V; Braham S; Tosetti G; Branchi F; Bitto N; Moia M; Fracanzani AL; Colombo M; Tripodi A; Primignani M
    Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1146-1152.e4. PubMed ID: 29066371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.